ESLA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States...

Stats
Today's Volume	24 529.00
Average Volume	28 256.00
Market Cap	37.16M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.07
ATR14	$0.0280 (2.76%)

Insider Trading

Date	Person	Action	type
2023-09-29	Xu Jiandong	Sell	Common Stock
2023-09-29	Roberts Marsha	Buy
2023-09-29	Xu Pei	Buy
2023-09-29	Liu Cheng	Sell	Common Stock
2023-09-29	Wu Xuejun Janelle	Buy

INSIDER POWER
-100.00
Last 9 transactions
Buy: 141 970 \| Sell: 255 000

Estrella Immunopharma, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Estrella Immunopharma, Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.170

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.170

Financial Reports:

No articles found.

Estrella Immunopharma, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Estrella Immunopharma,

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.